TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31141115

Group type: EXPERIMENTAL
Intervention: Cinematic Rendering (CR)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Computed Tomography (CT)
Number of subjects: 40
Study: 27685757

Group type: EXPERIMENTAL
Intervention: HPV testing with liquid-based cytology (LBC) triage for HPV positives
Number of subjects: 25152

Group type: COMPARATOR
Intervention: Control arm - Baseline liquid-based cytology (LBC) with ASCUS results triaged with HPV testing
Number of subjects: 25152

Group type: EXPERIMENTAL
Intervention: HPV testing with LBC triage for HPV positives
Number of subjects: 25152

Group type: EXPERIMENTAL
Intervention: HPV testing with LBC triage for HPV positives in women ≥35 years
Number of subjects: 25152

Group type: EXPERIMENTAL
Intervention: HPV testing in women 25-29
Number of subjects: 25152
Study: 25971394

Group type: EXPERIMENTAL
Intervention: Mild hypothermia (core temperature 34.5-35°C)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Normothermia (core temperature 36.5-37°C)
Number of subjects: 60
Study: 23926587

Group type: EXPERIMENTAL
Intervention: 1-stage lateral window sinus lift with simultaneous implant placement
Number of subjects: 60

Group type: COMPARATOR
Intervention: 2-stage procedure with implant placement delayed by 4 months
Number of subjects: 60
Study: 21307655

Group type: EXPERIMENTAL
Intervention: HibMenCY‐TT
Number of subjects: 606

Group type: COMPARATOR
Intervention: Hib‐TT
Number of subjects: 606
Study: 19037018

Group type: EXPERIMENTAL
Intervention: Subtraction MR images
Number of subjects: 40

Group type: COMPARATOR
Intervention: Native MR images
Number of subjects: 40
Study: 17338822

Group type: EXPERIMENTAL
Intervention: Generalist care manager (GCM) intervention
Number of subjects: 45

Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 45
Study: 15472162

Group type: EXPERIMENTAL
Intervention: Frailty as a selection criterion
Number of subjects: 0

Group type: COMPARATOR
Intervention: Chronological age as a selection criterion
Number of subjects: 0
Study: 11218582

Group type: EXPERIMENTAL
Intervention: Ureaplasma urealyticum colonization
Number of subjects: 59

Group type: COMPARATOR
Intervention: Ureaplasma urealyticum negative
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Ureaplasma urealyticum colonization in infants with birth weight of 1,000 g or less
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Ureaplasma urealyticum colonization in infants with patent ductus arteriosus
Number of subjects: 59
Study: 9396895

Group type: EXPERIMENTAL
Intervention: 100 micrograms of intravaginal misoprostol
Number of subjects: 75

Group type: COMPARATOR
Intervention: 5 mg of pharmacy-prepared intravaginal prostaglandin E2 gel
Number of subjects: 75
Study: 8187445

Group type: EXPERIMENTAL
Intervention: Prospidine (500 mg every 3-5 days intravenously, then monthly)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Methotrexate (30 mg/week intravenously in hospital, then orally 7.5-15 mg/week)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Prospidine
Number of subjects: 27

Group type: COMPARATOR
Intervention: Methotrexate
Number of subjects: 27

Group type: COMPARATOR
Intervention: Prospidine and Methotrexate
Number of subjects: 27
Study: 3492164

Group type: EXPERIMENTAL
Intervention: Antibiotic therapy
Number of subjects: 173

Group type: COMPARATOR
Intervention: Placebo therapy
Number of subjects: 173
Study: 31603201

Group type: EXPERIMENTAL
Intervention: EBOV GP vaccine with Matrix‐M adjuvant (2 doses)
Number of subjects: 230

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 230
Study: 29924240

Group type: EXPERIMENTAL
Intervention: U-MDT regimen (six doses of MB-MDT: rifampicin, dapsone, and clofazimine)
Number of subjects: 753

Group type: COMPARATOR
Intervention: R-MDT regimen (six doses for PB: rifampicin and dapsone; 12 doses for MB: rifampicin, dapsone, and clofazimine)
Number of subjects: 753

Group type: COMPARATOR
Intervention: R-MDT regimen
Number of subjects: 753

Group type: EXPERIMENTAL
Intervention: U-MDT regimen
Number of subjects: 753
Study: 27367750

Group type: EXPERIMENTAL
Intervention: Tacrolimus maintenance arm
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo arm
Number of subjects: 10
Study: 25557189

Group type: EXPERIMENTAL
Intervention: Acute psychosocial stress task
Number of subjects: 45

Group type: COMPARATOR
Intervention: Non-stress control condition
Number of subjects: 45
Study: 21541732

Group type: EXPERIMENTAL
Intervention: 2.4 g/day CLA mixture (36.9% cis-9, trans-11 and 37.9% trans-10, cis-12)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo (2.4 g olive oil/day)
Number of subjects: 29
Study: 19282299

Group type: EXPERIMENTAL
Intervention: Rocuronium 0.3 mg kg(‐1)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Rocuronium 0.6 mg kg(‐1)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Rocuronium 0.9 mg kg(‐1)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Rocuronium 1.2 mg kg(‐1)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Rocuronium (all doses)
Number of subjects: 44
Study: 18055735

Group type: EXPERIMENTAL
Intervention: Advance provision of emergency contraception
Number of subjects: 6389
Study: 14675064

Group type: EXPERIMENTAL
Intervention: 4 mg of zoledronic acid (ZOL)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 12003652

Group type: EXPERIMENTAL
Intervention: Weekly iron tablets (65 mg of iron and 0.25 mg of folic acid) given for 10 weeks
Number of subjects: 1113

Group type: COMPARATOR
Intervention: No iron tablets (control group)
Number of subjects: 1113

Group type: COMPARATOR
Intervention: No specific intervention for untreated girls (control group)
Number of subjects: 1113

Group type: COMPARATOR
Intervention: No specific intervention for untreated boys (control group)
Number of subjects: 1113
Study: 9689339

Group type: EXPERIMENTAL
Intervention: Astemizole (10 mg o.d.)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Loratadine (10 mg o.d.)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study: 7980837

Group type: EXPERIMENTAL
Intervention: Cassava-salt suspension (CSS)
Number of subjects: 132

Group type: COMPARATOR
Intervention: WHO recommended ORS
Number of subjects: 132
Study: 2510271

Group type: EXPERIMENTAL
Intervention: Rioprostil, 600 micrograms nocte
Number of subjects: 208

Group type: COMPARATOR
Intervention: Ranitidine, 300 mg nocte
Number of subjects: 208
Study: 1157717

Group type: EXPERIMENTAL
Intervention: Low doses of heparin
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: Calcium heparinate (conventional high doses)
Number of subjects: 225

Group type: COMPARATOR
Intervention: Control group (no anticoagulants)
Number of subjects: 225
Study: 31067718

Group type: EXPERIMENTAL
Intervention: Sodium selenite (500 μg IV injections)
Number of subjects: 26

Group type: COMPARATOR
Intervention: 0.9% saline (control group)
Number of subjects: 26
Study: 29861395

Group type: EXPERIMENTAL
Intervention: CBDCA with nab-PTX (100 mg/m2 I.V. on days 1, 8, and 15 of each 21-day cycle)
Number of subjects: 250

Group type: COMPARATOR
Intervention: DOC (60 mg/m2 intravenous [I.V.] on day 1)
Number of subjects: 250
Study: 27185685

Group type: EXPERIMENTAL
Intervention: Prone position with IV ephedrine
Number of subjects: 56

Group type: COMPARATOR
Intervention: Supine position with IV ephedrine
Number of subjects: 56
Study: 23238880

Group type: COMPARATOR
Intervention: 125-Hz sinusoidal vibration at 0 ms(‐2) rms
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 125-Hz sinusoidal vibration at 22 ms(‐2) rms
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 125-Hz sinusoidal vibration at 88 ms(‐2) rms
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 2-N force with vibration (7.5 or 15 min)
Number of subjects: 0

Group type: COMPARATOR
Intervention: 2-N force without vibration
Number of subjects: 0
Study: 22157880

Group type: EXPERIMENTAL
Intervention: Aerobic exercise training
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Resistance exercise training
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Combination exercise training
Number of subjects: 204

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Fasting glucose
Number of subjects: 204
Study: 20301021

Group type: EXPERIMENTAL
Intervention: Drug-eluting stents (DES) - sirolimus-eluting stents (SES)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Bare metal stents (BMS)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Drug-eluting stents (DES)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Combined DES and BMS
Number of subjects: 23
Study: 17243915

Group type: EXPERIMENTAL
Intervention: Multivitamin supplementation (folic acid, B6, and B12) for 8 weeks
Number of subjects: 230

Group type: COMPARATOR
Intervention: Baseline measurements
Number of subjects: 230
Study: 16344029

Group type: EXPERIMENTAL
Intervention: Wheelchair Skills Training Program (WSTP)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 20
Study: 12587414

Group type: EXPERIMENTAL
Intervention: Hospital Anxiety and Depression Scale (HAD)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Test-retest of HAD
Number of subjects: 75
Study: 9889429

Group type: EXPERIMENTAL
Intervention: Nifedipine sustained-release tablets
Number of subjects: 13
Study: 7698384

Group type: EXPERIMENTAL
Intervention: Intrauterine insemination (IUI) after controlled ovarian hyperstimulation (COH)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Timed intercourse (TI) after controlled ovarian hyperstimulation (COH)
Number of subjects: 46
Study: 2664571

Group type: EXPERIMENTAL
Intervention: Defibrotide (400 mg i.v./i.m. b.i.d., starting the day before the surgery for 8 days)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Calcium heparin (5000 IU s.c. b.i.d., starting on the day of surgery, for 4 days)
Number of subjects: 102
Study: 357231

Group type: EXPERIMENTAL
Intervention: Ketoprofen
Number of subjects: 10
Study: 31860601

Group type: EXPERIMENTAL
Intervention: Deep neuromuscular blockade
Number of subjects: 88
Study: 31730474

Group type: EXPERIMENTAL
Intervention: Web survey
Number of subjects: 0

Group type: COMPARATOR
Intervention: Paper survey
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Brochure enclosure
Number of subjects: 0

Group type: COMPARATOR
Intervention: No brochure enclosure
Number of subjects: 0
Study: 27484763

Group type: EXPERIMENTAL
Intervention: Shuanghuang Shengbai Granule (SSG) for 14 days starting on the first day of chemotherapy
Number of subjects: 330
Study: 25807090

Group type: EXPERIMENTAL
Intervention: Allopurinol (100 mg daily for 14 days, then 200 mg daily for 14 days)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Allopurinol
Number of subjects: 31
Study: 23340351

Group type: EXPERIMENTAL
Intervention: Ropivacaine
Number of subjects: 236

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 236

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 236
Study: 21344260

Group type: EXPERIMENTAL
Intervention: Acetaminophen 2 g intravenously 30 min before surgery
Number of subjects: 76

Group type: COMPARATOR
Intervention: Placebo intravenously 30 min before surgery
Number of subjects: 76
Study: 18945577

Group type: EXPERIMENTAL
Intervention: Brachiocephalic arteriovenous fistula (BCAVF)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Brachiobasilic arteriovenous fistula (BBAVF)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (BCAVF)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (BBAVF)
Number of subjects: 100
Study: 17196358

Group type: EXPERIMENTAL
Intervention: Tailored telephone counseling
Number of subjects: 1244

Group type: EXPERIMENTAL
Intervention: Tailored print
Number of subjects: 1244

Group type: EXPERIMENTAL
Intervention: Tailored telephone counseling and print
Number of subjects: 1244

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1244
Study: 14689227

Group type: EXPERIMENTAL
Intervention: 100 ml of contrast material (CM) at 4 ml/s followed by 40 ml of saline chaser at 4 ml/s
Number of subjects: 42

Group type: COMPARATOR
Intervention: 140 ml of contrast material (CM) at 4 ml/s
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: 100 ml of CM with saline chaser
Number of subjects: 42

Group type: COMPARATOR
Intervention: 140 ml of CM
Number of subjects: 42
Study: 11870505

Group type: EXPERIMENTAL
Intervention: Cisplatin suspension (5 mg in 1 ml, 150 mg m(‐2), max 300 mg, max fluid 60 ml)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Usual cisplatin solution (150 mg m(‐2) dissolved in 500 ml saline)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Both groups received intravenous infusion of sodium thiosulphate (9 g m(‐2))
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Cisplatin suspension
Number of subjects: 30
Study: 9649985

Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 42

Group type: COMPARATOR
Intervention: Halothane
Number of subjects: 42
Study: 8031162

Group type: EXPERIMENTAL
Intervention: 5-FU tablets administered at a dose of 200 mg/day for 6 months
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: 5-FU tablets administered at a dose of 200 mg/day for 12 months
Number of subjects: 200

Group type: COMPARATOR
Intervention: Surgery alone (no chemotherapy)
Number of subjects: 200
Study: 2524386

Group type: EXPERIMENTAL
Intervention: xipamide 20 mg once daily
Number of subjects: 12

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 12
Study: 4574043

Group type: EXPERIMENTAL
Intervention: Craniospinal irradiation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 0
Study: 30295116

Group type: EXPERIMENTAL
Intervention: Acute tryptophan depletion (ATD)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Acute phenylalanine tyrosine depletion (APTD)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Balanced amino acid mixture (BAL)
Number of subjects: 49
Study: 31236943

Group type: EXPERIMENTAL
Intervention: Proposed modeling workflow for DVH prediction
Number of subjects: 268

Group type: EXPERIMENTAL
Intervention: Replanned cases guided by the proposed model
Number of subjects: 268

Group type: COMPARATOR
Intervention: Conventional knowledge-based model
Number of subjects: 268
Study: 28682918

Group type: EXPERIMENTAL
Intervention: Acupressure as an adjunctive therapy to sodium valproate (ASV)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Sodium valproate alone (SV)
Number of subjects: 98
Study: 25970485

Group type: EXPERIMENTAL
Intervention: Combined hyperbaric (4 mg) and hypobaric (6 mg) ropivacaine (Group A)
Number of subjects: 136

Group type: COMPARATOR
Intervention: Hyperbaric ropivacaine (Group B)
Number of subjects: 136
Study: 23108937

Group type: EXPERIMENTAL
Intervention: Caffeine (100 mg, then 150 mg)
Number of subjects: 369

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 369
Study: 21736751

Group type: EXPERIMENTAL
Intervention: Canakinumab 150 mg SC every 4 weeks
Number of subjects: 274

Group type: EXPERIMENTAL
Intervention: Canakinumab 300 mg SC every 2 weeks
Number of subjects: 274

Group type: EXPERIMENTAL
Intervention: Canakinumab 600 mg IV loading dose followed by 300 mg SC every 2 weeks
Number of subjects: 274

Group type: COMPARATOR
Intervention: Placebo SC every 2 weeks
Number of subjects: 274
Study: 19564303

Group type: EXPERIMENTAL
Intervention: Sleep-disordered breathing (SDB)
Number of subjects: 194
Study: 16401655

Group type: EXPERIMENTAL
Intervention: Ethanol (Eth; mean blood alcohol concentration at 60 min: 87.3, SD: 18.4)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Promethazine 30 mg (P30)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo (Pla)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Promethazine 20 mg (P20)
Number of subjects: 11
Study: 15501626

Group type: EXPERIMENTAL
Intervention: Remifentanil (0.25 microg/kg/minute) with target controlled infusion of propofol (target blood concentration: 1.5 to 2 microg/ml)
Number of subjects: 338

Group type: COMPARATOR
Intervention: Alfentanil (1 microg/kg/minute) with manually controlled infusion of propofol
Number of subjects: 338
Study: 11519700

Group type: EXPERIMENTAL
Intervention: Guided tissue regeneration (GTR)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Enamel matrix proteins (EMD)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Coronally repositioned flap surgery (control)
Number of subjects: 15
Study: 9283858

Group type: EXPERIMENTAL
Intervention: Heater probe
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Injection sclerosis
Number of subjects: 31

Group type: COMPARATOR
Intervention: Medical-surgical treatment
Number of subjects: 31
Study: 8518898

Group type: EXPERIMENTAL
Intervention: Angelchik prosthesis
Number of subjects: 119

Group type: COMPARATOR
Intervention: Floppy Nissen fundoplication
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Angelchik prosthesis (consecutive series)
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Angelchik prosthesis and floppy Nissen fundoplication
Number of subjects: 119
Study: 3552838

Group type: EXPERIMENTAL
Intervention: Streptokinase (SK)
Number of subjects: 11806

Group type: COMPARATOR
Intervention: Control (C)
Number of subjects: 11806
Study: 29540866

Group type: EXPERIMENTAL
Intervention: Stented pancreatico‐jejunostomy
Number of subjects: 102

Group type: COMPARATOR
Intervention: Non-stented pancreatico‐jejunostomy
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Soft pancreatic texture
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Pancreatic duct <3mm
Number of subjects: 102
Study: 27484507

Group type: EXPERIMENTAL
Intervention: Inspiratory muscle training loaded with 40% of maximum inspiratory pressure, readjusted weekly
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham intervention consisting of unloaded exercises
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Inspiratory muscle training
Number of subjects: 0
Study: 24626738

Group type: EXPERIMENTAL
Intervention: Early intervention group (indicated sample)
Number of subjects: 229

Group type: COMPARATOR
Intervention: Control group (indicated sample)
Number of subjects: 229

Group type: EXPERIMENTAL
Intervention: Early intervention group (selective high-risk sample)
Number of subjects: 229
Study: 22568863

Group type: EXPERIMENTAL
Intervention: GSK1482160 (up to 1 g, single doses)
Number of subjects: 29
Study: 20022990

Group type: EXPERIMENTAL
Intervention: Zoledronic acid (ZA) 4 mg iv every 3 months for 12 months
Number of subjects: 101

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 101
Study: 19246793

Group type: EXPERIMENTAL
Intervention: Vitamin E supplementation (400 IU twice daily)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo (standard therapy only)
Number of subjects: 24
Study: 15719740

Group type: EXPERIMENTAL
Intervention: Shentao Ruangan pill (SRP) combined with local perfusion of hydroxycamptothecine (HCPT)
Number of subjects: 85

Group type: COMPARATOR
Intervention: Transcatheter arterial chemoembolization (TACE)
Number of subjects: 85
Study: 12949315

Group type: EXPERIMENTAL
Intervention: Budesonide inhalation suspension 0.5 mg (total daily dose) once or twice daily
Number of subjects: 335

Group type: COMPARATOR
Intervention: Cromolyn sodium nebulizer solution 20 mg 4 times daily
Number of subjects: 335

Group type: EXPERIMENTAL
Intervention: Budesonide inhalation suspension
Number of subjects: 335

Group type: EXPERIMENTAL
Intervention: Budesonide inhalation suspension and cromolyn sodium
Number of subjects: 335

Group type: COMPARATOR
Intervention: Cromolyn sodium
Number of subjects: 335
Study: 10715305

Group type: EXPERIMENTAL
Intervention: (111)In-DTPA-D-Phe(1)-OCT
Number of subjects: 194
Study: 8941260

Group type: COMPARATOR
Intervention: Usual medical care
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Evidence-based, planned care; reorganization of practice systems; improved patient self-management support; increased access to expertise; greater availability of clinical information
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Integrated system of chronic illness care
Number of subjects: 0
Study: 1634632

Group type: EXPERIMENTAL
Intervention: Light energy conversion toothbrush with semiconductor of TiO2 (test)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Toothbrush without semiconductor (control)
Number of subjects: 73
Study: 6365017

Group type: EXPERIMENTAL
Intervention: Methadyl acetate three times a week (tiw) with placebos on alternate days
Number of subjects: 255

Group type: EXPERIMENTAL
Intervention: Methadyl acetate tiw supplemented with decreasing doses of methadone on alternate days
Number of subjects: 255

Group type: EXPERIMENTAL
Intervention: Methadyl acetate six days a week with diminishing doses on three days
Number of subjects: 255

Group type: COMPARATOR
Intervention: Supplementary methadyl acetate along with the regular dose
Number of subjects: 255

Group type: COMPARATOR
Intervention: Supplementing with methadone
Number of subjects: 255
Study: 30497530

Group type: EXPERIMENTAL
Intervention: neoadjuvant chemotherapy with bevacizumab
Number of subjects: 123

Group type: COMPARATOR
Intervention: neoadjuvant chemotherapy without bevacizumab
Number of subjects: 123
Study: 26724840

Group type: EXPERIMENTAL
Intervention: PSA ≥ 3.0 + MRI + TB
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: PSA ≥ 1.8 + MRI + TB
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: PSA ≥ 3.0 + MRI
Number of subjects: 124

Group type: COMPARATOR
Intervention: PSA ≥ 3.0 + SB
Number of subjects: 124
Study: 23632404

Group type: EXPERIMENTAL
Intervention: Topical brimonidine tartrate (BT)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Oral acetazolamide (ACZ)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Anterior chamber paracentesis (ACP)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 56
Study: 22633593

Group type: EXPERIMENTAL
Intervention: Zirconia (Lava) 3-unit posterior fixed dental prostheses
Number of subjects: 17
Study: 20339912

Group type: EXPERIMENTAL
Intervention: Parents of children with ADHD
Number of subjects: 124

Group type: COMPARATOR
Intervention: Parents of comparison youth
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Parental behaviors (socialization with other parents, facilitation of child's peer interactions)
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Parental corrective feedback and praise
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Parents' ratings of child's social skills
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Parental behaviors and peer relationships
Number of subjects: 124
Study: 18587144

Group type: EXPERIMENTAL
Intervention: Workshops on urine submission
Number of subjects: 82

Group type: COMPARATOR
Intervention: Modified laboratory forms
Number of subjects: 82

Group type: COMPARATOR
Intervention: Control workshop
Number of subjects: 82
Study: 16113791

Group type: EXPERIMENTAL
Intervention: Folic acid supplementation (0.8 mg/day) for 1 year
Number of subjects: 276

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 276